JAOA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

JAOA • Vol 104 • No 2_suppl • February 2004 • 11-16
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, G.
Right arrow Articles by Sussman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, G.
Right arrow Articles by Sussman, D.

A Current Review of Medical Therapy for Benign Prostatic Hyperplasia

GA Brown; DO Sussman

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease. Therapy for this disease has evolved considerably from its inception. Recent data from long-term population-based studies have shed new light on the treatment of this common problem in aging men. The authors review the current state of diagnosis of BPH and medical therapy for this condition in the primary care setting.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
S. M Setter, J. L Iltz, J. E Fincham, R K. Campbell, and D. E Baker
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Ann. Pharmacother., July 1, 2005; 39(7): 1286 - 1295.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Osteopathic Association.